Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

mber 31, 2012 was $46.2 million, or $0.66 and $0.62 income per basic and diluted earnings per share, respectively, compared to non-GAAP net income of $58.6 million, or $0.85 and $0.82 income per basic and diluted earnings per share, respectively for the quarter ended December 31, 2011.

Revenue for the six months ended December 31, 2012 was $160.7 million compared to $77.9 million for the six months ended December 31, 2011. Revenue for the quarter ended December 31, 2012 was $58.0 million compared to $77.9 million for the quarter ended December 31, 2011. Revenue for the quarter ended December 31, 2012 consisted primarily of $50.0 million of milestone revenue due to the Company's achievement of one clinical milestone in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") and $5.0 million of license revenue related to the Company's license agreement with Novo Nordisk A/S under which Novo Nordisk A/S acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a restricted disease indication outside of oncology.

To date, the Company has received three milestone payments from Janssen of $50 million each, totaling $150 million, under the Agreement. The Company may receive up to an additional $675 million in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year. Under the Agreeme
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... WIEN , July 3, 2015 /PRNewswire/ ... fram till 22 september 2015 på  http://www.openinnovationinscience.at ... Open Innovation in Science" som hålls i ... Enligt en färsk undersökning med internationella forskare ... Gesellschaft (LBG) är hälsovetenskapens två största utmaningar ...
(Date:7/3/2015)... July 3, 2015  Pomerantz LLP announces that a ... Inc. ("Puma" or the "Company")(NYSE: PBYI ) and ... United States District Court, Central District of ... behalf of a class consisting of all persons or ... and May 13, 2015 inclusive (the "Class Period").  This ...
(Date:7/2/2015)... ... ... Cuvettes have been used in countless labs for decades. In the past, people had ... As expected, this was a daunting and tiring process looking at endless data tables and ... to navigate the complex catalog structure. , Now thanks to FireflySci, scientists are throwing away ...
(Date:7/2/2015)... BETHESDA, Md. , July 2, 2015  Spherix ... committed to the fostering and monetization of intellectual property, ... matter of Spherix Incorporated v. Verizon Services Corp. ... States District Court for the Eastern District of ... Order on July 1, 2015 interpreting certain key claims ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4New Cuvette E-Commerce Website Launched by FireflySci 2Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3
...   Life Technologies Corporation (NASDAQ: LIFE ... with DaAn Gene, a leading Chinese company in molecular ... a joint venture diagnostics business in China. The move ... oncology, infectious diseases and genetic diseases. Financial terms of ...
... Corporation (Nasdaq: LMNX ) today announced that it ... year 2011 on Monday, February 6, 2012. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
... 16, 2012 Regenesis Biomedical, Inc., a medical ... announced today that Scott Brooks has joined the ... Operating Officer. Scott is responsible for helping scale ... and broadened reimbursement. (Logo: ...
Cached Biology Technology:Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China 2Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China 3Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China 4Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China 5Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012 2Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012 3Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer 2
(Date:6/18/2015)... 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market announces that its Wocket® smart ... "Money on the Mark", scheduled to air on WABC Radio ... 20 th . The broadcast air- time ... to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/17/2015)... GARDENS, Fla. , June 17, 2015 /PRNewswire/ ... solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... casual sandwich chain, to increase security, improve accountability ... fingerprint readers enable instant, non-repudiable identity confirmation for ...
(Date:6/16/2015)... -- Fingerprint Cards (FPC) raises the revenue guidance ... to at least 340 MSEK to that it will amount ... market growth and orders received the revenue guidance for 2015 ... 2015 will exceed 1,500 MSEK to an updated guidance that ... Due to receipt of orders of touch fingerprint sensors ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... Planck Institute for Chemical Ecology in Jena, Germany, have ... for 40 million years. Arum palaestinum , ... as pollinators by emitting odor molecules that resemble those ... yeast. The plant accomplishes the illusion of yeast simply ...
... agricultural scientists reported in today,s issue of the journal ... engineered to produce insect-killing proteins isolated from the soil ... benefits even to neighboring farmers who grow non-transgenic varieties ... is playing a critical role in addressing many of ...
... won a $1.175 million grant that will support its research ... who has spent his career looking for clues to the ... of gold, lead and other heavy atoms, said the Department ... and commissioning a highly complex detector system to using that ...
Cached Biology News:Deceitful lily fools flies 2Deceitful lily fools flies 3New study shows benefits of Bt corn to farmers 2Grant advances quark-gluon plasma studies
 2Grant advances quark-gluon plasma studies
 3
Fingerprinting II cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to the Fingerp...
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
... Ideal for hand-held applications or for use ... with a hand-held eight-port disposable manifold provides ... a multi-channel pipette. The StatMatic II can ... sizes and can completely fill a microplate ...
...
Biology Products: